StockData
DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

DEXCOM INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$85.98−0.06 (-0.07%)

Close on Oct 19, 2026

Market cap
$33.54B
P/E (TTM)
34.1
Dividend yield
–

Earnings

Next report expected Oct 29, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 30, 2026After market close$1.31B$0.64$0.70
Q1 FY2026
Ended Mar 31, 2026
Apr 30, 2026After market close$1.19B$0.51$0.56
Q4 FY2025
Ended Dec 31, 2025
Jan 12, 2026Before market open$1.26B––
Q3 FY2025
Ended Sep 30, 2025
Oct 30, 2025After market close$1.21B$0.70$0.61
Q2 FY2025
Ended Jun 30, 2025
Jul 30, 2025After market close$1.16B$0.45$0.48
Q1 FY2025
Ended Mar 31, 2025
May 1, 2025After market close$1.04B$0.27$0.32
Q4 FY2024
Ended Dec 31, 2024
Jan 13, 2025Before market open$1.11B––
Q3 FY2024
Ended Sep 30, 2024
Oct 24, 2024After market close$994.20M$0.34$0.45
Q2 FY2024
Ended Jun 30, 2024
Jul 25, 2024After market close–––
Q1 FY2024
Ended Mar 31, 2024
Apr 25, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Feb 8, 2024After market close–––

Company guidance

Outlook given with results on Jul 30, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Non-GAAP Gross Profit Marginnon-GAAPfiscal year 202664%Raised
Non-GAAP Operating Marginnon-GAAPfiscal year 202623.5% to 24%Raised
Adjusted EBITDA Marginnon-GAAPfiscal year 202631.5% to 32%New
Revenuefiscal year 2026$5.18B to $5.25BRaised
Revenue growthfiscal year 202611% to 13% growthMaintained

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Dexcom filed with the SEC